News: Basilea

News

News Subscription

Jul 14. 2014

Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections

Read more

Jul 10. 2014

Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis

Read more

Jun 26. 2014

Basilea announces start of phase 2a study with oncology drug candidate BAL101553

Read more

Jun 25. 2014

Basilea provides update on ceftobiprole's U.S. regulatory status

Read more

Jun 13. 2014

Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem

Read more

Jun 12. 2014

Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem

Read more

Jun 02. 2014

Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study

Read more

May 14. 2014

Basilea reports additional data on positive isavuconazole phase 3 SECURE study at ECCMID

Read more

May 13. 2014

Basilea presents new data on its antibiotics pipeline at ECCMID

Read more

Apr 10. 2014

Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.

Read more

previous
1
…
28
29
30
…
32
next